Syntekabio Receives "Unqualified" Opinion in 2025 Audit Report...Meets Revenue Requirements and Resolves Administrative Issue Risk

AI drug development company Syntekabio announced on March 20, 2026, that it had demonstrated both financial soundness and business stability after receiving an "unqualified" opinion in its 2025 audit report.

According to a disclosure made the previous day, Syntekabio stated that it had received an unqualified opinion from its external auditor. The company also explained that it satisfied all listing maintenance requirements for KOSDAQ, including sales revenue, pre-tax loss, and capital impairment ratio.

On a consolidated basis for 2025, the company reported sales of 3,429 million won. This figure represents an increase of over 2,700% compared to the previous year, attributed to the full-scale monetization of its AI drug development platform and related services.

Since entering the KOSDAQ market in December 2019 through a technology exception, the company had been required to achieve annual sales of at least 3 billion won. With this latest result surpassing the threshold, uncertainties regarding potential designation as an administrative issue have also been resolved.

In terms of profitability, the improvement trend continued. Operating loss for 2025 was approximately 10.7 billion won, still in the red, but down by about 75% from the previous year, significantly reducing the scale of losses. This suggests that both sales growth and some cost efficiency measures produced tangible results, indicating ongoing structural improvement.

On the other hand, net loss widened. The company explained that this was due to a decline in derivative valuation gains that had been reflected in the previous year, as well as changes in financial expense structure stemming from an increase in short-term borrowings. The company added that these are accounting factors with little direct relevance to operating activities and should be distinguished from the substantial trends of sales growth and reduced operating losses.

By meeting the key sales requirements through this audit report, the company has also secured listing stability.

A company official stated, "With the unqualified audit opinion and achieving over 3 billion won in sales, we have been able to alleviate concerns about being designated as an administrative issue. Since last year, our business has entered a stabilization phase, and we have demonstrated to the market an improvement in our financial structure based on external growth."

The official added, "This year, we are pursuing diversification of our business portfolio centered on a data center-based AI drug development platform, including asset programs and PaaS models. We plan to continue expanding sales and improving profitability over the medium to long term."

This content was produced with the assistance of AI translation services.